| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $1.0M | — |
| Cost of Revenue | $3.0M | — |
| R&D Expense | $11.2M | -33.7% |
| SG&A Expense | $11.0M | -13.8% |
| Operating Income | -$24.2M | +18.4% |
| Net Income | -$23.7M | +19.0% |
| EPS (Basic) | -$3.94 | -525.4% |
| EPS (Diluted) | -$3.94 | -525.4% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $7.9M | +29.2% |
| Inventory | $2.0M | +83.7% |
| Current Assets | $10.4M | +21.9% |
| Total Assets | $11.3M | +20.2% |
| Current Liabilities | $3.4M | -41.6% |
| Total Liabilities | $4.0M | -33.6% |
| Stockholders' Equity | $7.4M | +113.3% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$22.5M | +13.9% |
| Capital Expenditures | $8K | -87.5% |
| Investing Cash Flow | -$8K | +87.5% |
| Financing Cash Flow | $24.3M | +12.6% |
| Free Cash Flow | -$22.5M | +14.1% |